Picture loading failed.

Pre-Made Labetuzumab biosimilar, Whole mAb ADC, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-288-1mg 1mg Inquiry
GMP-Bios-ab-288-10mg 10mg Inquiry
GMP-Bios-ab-288-100mg 100mg Inquiry
GMP-Bios-ab-288-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Labetuzumab biosimilar, Whole mAb ADC, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody
INN Name Labetuzumab
TargetCD66e
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesImmunomedics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedColorectal cancer;Ovarian cancer;Breast cancer
Development Techna